 |
BioWorld-International-2008-04-23
MTM Adds $15M to Series C for Biomarker-based Assays
MTM Adds $15M to Series C for Biomarker-based Assays
MTM Laboratories AG added another E9.6 million (US$15.3 million) to its Series C financing round, taking the total to E31.6 million and giving the company additional funds for further clinical development of its biomarker-based diagnostic assays for cervical cancer and for building out its sales and marketing infrastructure. (BioWorld International)